Summary. -Th e current study was designed to determine the role of the host genes involved in the development of chronic hepatitis C-associated type 2 diabetes mellitus. Th is study was carried out in patients in four diff erent stages of chronic hepatitis C virus (HCV) infection, including treatment-naïve HCV patients, HCV-positive patients with type 2 diabetes mellitus (T2DM), non-responders and responders. Th e mRNA expression level of host genes, such as glucose-6-phosphatase (G6Pase), tumor necrosis factor α (TNF-α) and diff erent adipokines including adiponectin, leptin and resistin, was quantifi ed and compared to healthy controls. HCV infection was found to be associated with insulin resistance, a step towards type 2 diabetes mellitus (T2DM). Th e results also suggest the potential role of adipokines in chronic HCV (CHC)-associated T2DM. Th e upregulation of gluconeogenic genes, such as G6Pase and resistin, and a decreased mRNA expression level of adiponectin suggest the potential role of selected markers in the CHC-associated T2DM in Pakistani population. Based on these results, it is concluded that upregulation of TNF-α, G6Pase and resistin in chronic HCV patients leads to gluconeogenesis, eventually favoring T2DM. Collectively, these fi ndings suggest that CHC patients are more prone to T2DM.
Introduction
Hepatitis C virus (HCV) is a lethal blood-bore pathogen that shows hepatotropism. Once infection is established, it can progress from acute to chronic, eventually advancing in multiple hepatological disorders including fi brosis, cirrhosis, steatosis, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and hepatocellular carcinoma (HCC) (Lau et al., 1998; Bièche et al., 2005; Fartoux et al., 2005; Pekow et al., 2007) . Th e morbidity rate of patients infected with HCV is more than 170 million, making about 3% of the world's population (Simmonds, 2004) .
Insulin is an anabolic hormone that aids in selective absorption of glucose and maintains normal blood glucose level. Th is involves a complex array of metabolic signaling, where insulin receptor substrate (IRS) acts as an adaptor protein and couples insulin to the cytosolic domain of insulin receptor. Any artifact in this signaling pathway is likely to disrupt the glucose metabolism and favors insulin resistance, T2DM as well as lipogenesis (Parvaiz et al., 2014) .
HCV core and NS5A proteins are considered to be the potential candidates towards IR development (Banerjee et al., 2008; Parvaiz et al., 2014) . Under normal insulin signaling, activation of IRS involves phosphorylation at tyrosine residues, while serine phosphorylation is favored during infection or disrupted metabolic signaling (Withers, 2001; White, 2003) . Previous studies have shown that upregulation of TNF-α triggers serine phosphorylation of the IRS, thereby modulating entire downstream insulin signaling pathway. IL-6 and TNF-α are important proinfl ammatory cytokines that are upregulated in CHC patients (AlDosary et al., 2002) . Previous studies have also indicated a plausible role of TNF-α in T2DM (Saliba et al., 2007) .
Contrary to the infl ammation, naturally various antiinfl ammatory mediators, such as adiponectin, IL-10, IL-6, etc. are activated in HCV infection (Tilg and Moschen, 2006) . Previous studies have also linked the resistin-mediated upregulation of TNF-α with infl ammation (Silswal et al., 2005) . Some studies have also linked the upregulation of TNF-α with increased gluconeogenic gene expression, such as G6Pase and phosphoenolpyruvate carboxykinase (PEPCK). PEPCK is a rate-limiting step for gluconeogenesis that converts pyruvate back to glucose, eventually favoring increased blood glucose level. (Deng et al., 2010) .
Th e molecular mechanism behind HCV-induced IR is still a great mystery. Pakistan is an under-developed country with great challenges in morbidity and mortality due to HCV infection. Th is study was designed to unveil plausible markers involved in CHC-induced IR in Pakistani population. 
Materials and Methods
Study design. In this study, 36 patients chronically infected with HCV were screened and analyzed. Th e patients were categorized into four diff erent groups depending upon their response to the standard therapy for HCV. First group included 10 treatment-naïve (TN) chronic HCV patients (Table 2) , second group 10 treatment non-responders without T2DM (NR) ( included 6 treatment non-responders with T2DM (NR-T2DM) (Table 4 ) and the fi nal group of 10 patients, who achieved sustained virological response (SVR) aft er the treatment (Table 5) . Th e control group included 15 healthy individuals (HCV negative). Th e treatment off ered to patients was in accordance with the standards of care set for the HCV genotype 3 infections. Patients were given pegylated interferon along with ribavirin for 24 weeks. Th e study design was approved by the ethical committees of the Combined Military Hospital (CMH), Military Hospital (MH) Rawalpindi, and the Atta-ur-Rahman School of Applied Biosciences (ASAB) NUST Islamabad, Pakistan. Blood collection. Blood samples positive for hepatitis C virus infection were collected within a period of 10 months. Patients with adequate documentation of abnormal ALT for over 6 months, anti-HCV antibody and blood sugar estimation were included in the study. Patients infected with HCV (both male and female) genotype 3a, with age ≥ 25 years, were included. Th e blood samples from these patients were subjected to a series of biochemical analyses, such as genotyping, complete blood count, lipid profi le, liver function tests and hemoglobin A1c (HbA1c) diagnostic test for diabetes, in Armed Forces Institute of Pathology (AFIP), Rawalpindi. PCR-based confi rmation of HCV RNA was performed in ASAB diagnostic laboratories. Th e quantifi cation of HCV RNA was carried out by real time PCR according to the manufacturer's protocol using Applied Biosciences 7300 Real time PCR System (Imran et al., 2015) . Th e samples were run in parallel along with the quantifi cation standards (synthetic internal controls). HCV RNA level in each sample was quantifi ed with help of CT values for the sample and standard curve resulting from the analysis of quantifi cation standard and the assay-specifi c calibration coeffi cient. Th e HCV RNA concentration is expressed in IU/ml, where one IU/mL is equal to two RNA copies/ml. Th e genotype of the virus was determined using genotype-specifi c primers reported by Ohno et al. (1997) . Patients with co-infection of HBV, HIV or any other associated liver disease were excluded from this study. A written consent form was duly signed by the patients, healthy controls and ethical committee.
RNA extraction, quantifi cation and reverse transcription. Total cellular RNA was extracted from blood of patients and healthy controls using TRIZOL method according to manufacturer's protocol. To avoid cellular contamination, the extracted RNA was treated with DNAase I (Fermentas, MD, USA). To determine quality and quantity, the extracted RNA was subjected to spectrophotometry (Eppendorf BioPhotometer plus™). Th e complementary cDNA strand was synthesized from DNase I-treated RNA using oligo (dT) 18 primer (Fermentas) and RevertAid H minus reverse transcriptase (Fermentas, MD, USA) in the presence of Ribolock RNase Inhibitor (Fermentas).
Optimization of PCR amplifi cation and quantifi cation. Th e gene expression of selected markers (TNF-α, resistin, leptin, adiponectin and G6Pase) was analyzed by PCR amplifi cation using primers 
specifi c for selected markers, designed in Primer3web soft ware Version 4.0.0 (Untergasser et al., 2012) . Primer sequences are listed in Table 1 o C (40 s)] and fi nal extension at 72 o C for 7 min. Results were validated by using multiple samples to ensure the consistency, and high concentration of the template cDNA was used so that the variation in the expression of the selected markers can be detected. PCR amplifi cation products were visualized on 2% agarose gel stained with ethidium bromide.
For the quantifi cation of selected cellular genes in a signaling pathway, PCR for each gene was optimized using 1 μg of cDNA. Amplifi cation plots for all genes were optimized by qRT-PCR in Applied Biosystems 7300 Real-Time PCR System using Maxima® SYBR Green/ ROX qPCR Master Mix (Fermentas, USA). Gene expression data was normalized to the expression levels of control or "housekeeping" genes. GAPDH was used as a housekeeping gene, a constitutive gene, expressed in all cells of the body. Th e relative gene expression analysis was carried out using the 2 -ΔΔCT method to calculate the fold change of diff erence. Each individual experiment was performed in triplicate.
Statistical analysis. All statistical tests were performed using Graph-Pad Prism version 5.0 (GraphPad Soft ware, Inc., CA, USA). Data are presented as mean ± standard error of the mean. Th e expression of the selected markers in the CHC patient samples and healthy controls was compared statistically by unpaired Student's t test. p-values <0.05 were considered statistically signifi cant (p <0.05, p <0.01 and p <0.001).
Results
To determine the regulatory genes involved in HCVinduced T2DM, selected genes were quantifi ed using quantitative real time PCR.
Quantifi cation of targeted genes in chronic HCV patients with and without T2DM
To understand the regulatory role of pro-infl ammatory cytokines and adipokines in CHC patients, qRT-PCR was performed along with healthy controls. Th ese CHC patients were without T2DM and categorized as treatmentnaïve (received no HCV treatment) and non-responders Gene expression of treatment naïve chronic HCV patients compared to that of healthy controls All values are expressed as mean ± SEM. TNF-α showed signifi cantly decreased (0.22-fold) expression, while AdipoQ (Adiponectin), Lep (Leptin) and RETN (Resistin) levels in CHC-associated diabetes non responders as compared to the healthy controls showed signifi cant increase (0.27-0.26-and 0.29-fold respectively). G6P levels showed no signifi cant change. ***shows p <0.001, **shows p <0.01, *shows p <0.05. Th e expression was studied at least in 3 separate studies with similar results. All reactions were set up in duplicate.
(HCV-positive aft er receiving standard HCV treatment as mentioned in the Materials and Methods section). Th e results indicated a signifi cantly reduced transcriptional level of TNF-α in treatment-naïve patients, while a signifi cant increase in expression was found in non-responder group in comparison with healthy controls (Fig. 1 and 2) . Th e data also suggest a decreased transcriptional expression of G6P in both groups, as T2DM has not developed yet ( Fig. 1  and 2) . Furthermore, data have also suggested a decreased transcriptional expression of adipokines in both targeted groups as compared to healthy controls ( Fig. 1 and 2) .
Th e results suggested a signifi cantly increased mRNA expression of TNF-α (1.94-fold), G6Pase (1.92-fold) and resistin (1.95-fold), while the Adiponectin mRNA expression levels (0.27-fold) were decreased signifi cantly in NR-T2DM patients compared to the healthy controls (Fig. 3) .
Expression level of targeted genes in SVR
Th e analysis of the selected markers in SVR and healthy controls revealed that the expression of mRNA of TNF-α (0.11-fold), G6Pase (0.25-fold), Lep (0.41-fold) and resistin (0.06-fold) decreased signifi cantly in SVR, while there was a signifi cant increase in the mRNA expression levels of Adiponectin in this group (Fig. 4) .
Discussion
HCV-associated T2DM is considered to be the outcome of chronic HCV infection (Hoofnagle, 2002) . Several studies have reported that HCV infection induces ER stress and promotes hepatic gluconeogenesis, resulting in increased Gene expression of non-responder chronic HCV patients compared to that of healthy controls All values are expressed as mean ± SEM. TNF-α showed signifi cantly enhanced (2.38-fold) expression, while G6P, ADIPOQ (Adiponectin), Lep (Leptin) and RETN (Resistin) levels in CHC-associated diabetes non responders as compared to the healthy controls remained unchanged. ***shows p < 0.001, **shows p <0.01, *shows p <0.05. Th e expression was studied at least in 3 separate studies with similar results. All reactions were set up in duplicate.
Fig. 3
Gene expression of chronic HCV-associated diabetic patients compared to that of healthy controls All values are expressed as mean ± SEM. TNF-α, G6P and RETN (Resistin) were increased signifi cantly (1.94-, 1.92-and 1.95-fold respectively), while Lep (Leptin) levels in CHC-associated diabetes non responders as compared to the healthy controls remained unchanged. Th e levels of ADIPOQ (Adiponectin) were signifi cantly decreased (0.27-fold). ***shows p< 0.001, **shows p <0.01, *shows p <0.05. Th e expression was studied at least in 3 separate studies with similar results. All reactions were set up in duplicate.
glucose production in hepatocytes, eventually leading to T2DM (Deng et al., 2011) .
Current study is focused on determining the role of several host genes in HCV-associated T2DM. Th e results of our study suggest an increase in the mRNA expression of TNF-α in non-responders with and without T2DM association. Th ese results are in accordance to the previous study that indicates an upregulation of oxidative stress during HCV infection (Parvaiz et al., 2011) . One of the possible mechanisms, through which these cytokines block normal insulin signaling, is the phosphorylation of IRS that modulates entire downstream insulin signaling pathway (Parvaiz et al., 2011) .
G6Pase is one of the important enzymes favoring gluconeogenesis. Th e G6Pase elevation in non-responder patients with T2DM correlated with the decreased glucose utilization and favors hyperglycemia (Shlomai et al., 2012) . Our results also suggested increased G6P expression.
Adiponectin and resistin are important adipokines that play pivotal role during infl ammation. (Durazzo et al., 2013) . Our data suggest somewhat varied expression of adipokines in diff erent categories of chronic HCV patients. TNF-α was found to be upregulated in NR and NR-T2DM. Our results indicated that there is no change in the expression of G6Pase in TN and NR groups, while an increased expression was observed in HCV-associated T2DM patients, revealing that there is strong role of G6Pase in the glucose impairment. Adiponectin is thought to have a hepatoprotective role and is found to be downregulated during hepatocyte damage (Kukla et al., 2011) . We also observed an increased expression of adiponectin in responders group, while a decreased expression of adiponectin was observed in patients with CHC-associated T2DM. Conversely, resistin was shown to have increased expression in HCV-associated T2DM patients, while decreased expression was observed in SVR. Gene expression of HCV responders compared to that of healthy controls All values are expressed as mean ± SEM. TNF-α, G6P, Lep (Leptin) and RETN (Resistin) levels in CHC responders as compared to the healthy controls were signifi cantly decreased (0.11-, 0.25-, 0.41-and 0.06-fold, respectively) . Th e level of ADIPOQ (Adiponectin) was enhanced signifi cantly (3.24-fold). ***shows p <0.001, **shows p <0.01, *shows p <0.05. Th e expression was studied at least in 3 separate studies with similar results. All reactions were set up in duplicate.
Th e expression levels of each of the four categories of patients have been compared and shown in Table 6 .
Present study demonstrated the molecular mechanism involving adipokines in HCV pathogenesis, leading towards HCV-associated T2DM. Based on these fi ndings, it is suggested that HCV induces insulin resistance, which down-regulates the expression of adipokines. Th is study also suggests the disease condition can be detected at early stages by evaluating the mRNA expression levels of the selected markers. Th e expression levels of certain cytokines and adipokines are affected due to the complexity of the metabolic pathways and the various transcription factors involved in them, showing the disease trend towards T2DM in chronic liver disease patients. Th e current study illustrates the need to investigate the roles of other adipokines in inducing HCV-associated T2DM to unveil the molecular pathways abrogated or perturbed by these events, leading to a more severe disease.
